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Purpose: Posterior capsular opacification (PCO) is a common long-term complication of modern cataract surgery.
Remnant lens epithelial cells (LECs) undergo a myofibroblast transdifferentiation that is thought to be the initial step of
PCO pathogenesis. The purpose of this study is to determine the effects of zebularine on transforming growth factor-β
(TGFβ)-induced, LEC-myofibroblast transdifferentiation.
Methods: The expression levels of methyl CpG binding protein 2 (MeCP2) and α-smooth muscle actin (α-SMA) in human
PCO membranes were evaluated by confocal microscopy. The role that MeCP2 played in TGFβ2-induced α-SMA
expression was analyzed by western blotting both before and after MeCP2 knockdown with MeCP2-specific siRNA. The
effect of zebularine on MeCP2 expression was analyzed over time using a variety of dosages. The effect of zebularine on
TGFβ2-induced α-SMA expression was determined by western blot analysis.
Results: MeCP2 and α-SMA co-localized in human PCO membranes. When MeCP2 was depleted, TGFβ2 could not
induce α-SMA expression. Zebularine decreased MeCP2 expression in lens epithelial cells in a time- and dose-dependent
pattern and reversed TGFβ2-induced α-SMA expression.
Conclusions: MeCP2 plays an important role in TGFβ2-induced α-SMA expression in lens epithelial cells. Zebularine
could reverse the TGFβ2-induced α-SMA expression by inhibiting MeCP2 expression. Therefore, zebularine could
potentially prevent PCO formation.
Posterior capsular opacification (PCO), also known as
secondary cataract, is a common long-term complication of
modern  cataract  surgery  [1,2].  Decreased  visual  acuity
induced by PCO is reported to occur in 20% to 40% of patients
two  to  five  years  after  surgery  [2,3].  Presently,  the  only
effective treatment of PCO is Nd:YAG laser capsulotomy.
However, complications include retinal detachment, damage
to  the  intraocular  lens,  and  cystoid  macular  edema  [4,5].
Therefore,  a  better  understanding  of  the  pathogenic
mechanism of PCO and effective treatments to prevent PCO
are highly desirable.
PCO is caused mainly by remnant lens epithelial cells
(LECs),  which  undergo  an  epithelial  cell-myofibroblast
transdifferentiation  (EMT),  followed  by  enhanced
proliferation, migration, and collagen deposition. During the
process of epithelial cell-myofibroblast transdifferentiation,
an epithelial cell undergoes phenotypic changes to resemble
a mesenchymal cell and expresses alpha smooth muscle actin
(α-SMA)  as  a  molecular  marker.  Although  inflammatory,
fibrogenic growth factors and cytokines produced by injured
tissues help to orchestrate the process of EMT, transforming
growth factor β (TGFβ) is believed to play a central role in the
process  [6-9].  Recently,  it  has  been  reported  that  DNA
methylation is an important mechanism of the α-SMA gene
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expression during myofibroblast differentiation, suggesting
that the epithelial cell-myofibroblast transdifferentiation is
also regulated by epigenetic factors [10].
Epigenetic  regulation  of  gene  expression  commonly
occurs at two primary levels: DNA methylation and histone
modifications. Methyl CpG binding protein 2 (MeCP2), a key
member  of  the  methyl-DNA  binding  protein  family  of
proteins, has been suggested as essential for myofibroblast
differentiation [11]. While MeCP2 can bind to unmethylated
DNA, it preferentially binds to methylated DNA at 5′-CpG
residues  [11].  MeCP2  was  originally  considered  a
transcriptional repressor but was later found also to have a
significant  role  as  a  transcriptional  activator.  In  addition,
MeCP2 functions in the regulation of chromatin architecture
and RNA splicing [12].
Zebularine  (1-(b-D-ribofuranosyl)-1,2-
dihydropyrimidin-2-one)  has  been  established  as  a  novel
inhibitor of DNA methyltransferase (DNMT) [13]. In contrast
to other DNMT inhibitors, it is quite stable [14,15] and has
low toxicity [16-18]. Preclinical studies using zebularine have
shown favorable toxicity and stability profiles, making it an
attractive candidate for epigenetic treatment of PCO [17].
In the present study, we investigated the role of MeCP2
in LEC epithelial cell-myofibroblast transdifferentiation. The
effects  of  zebularine  on  MeCP2  expression  and  TGFβ2-
induced  LEC  epithelial-mesenchymal  transitions  were
analyzed. The purpose of this study was to investigate whether
zebularine can be used to prevent PCO.
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The institutional review board (IRB) of the Fudan University
Eye and ENT Hospital (Shanghai, P.R. China) approved our
use of PCO membrane from donated eyes and cultured human
lens epithelial cells (LECs). All procedures conformed to the
Declaration  of  Helsinki  for  research  involving  human
subjects.  Zebularine  was  a  kind  gift  from  Dr.  Victor  E.
Marquez  (Laboratory  of  Medicinal  Chemistry,  National
Cancer Institute, Frederick, MD).
Immunofluorescent  staining:  Three  posterior  capsular
membranes were obtained from donated eyes with PCO one
year after cataract surgery. Immunofluorescent staining was
performed as previously described [19]. In brief, tissues were
snap-frozen and sectioned at 6 μm using a cryostat. Thawed
tissue sections were air-dried and rehydrated with PBS (pH
7.4). The slides were fixed with 3.7% paraformaldehyde for
30 min and then rinsed in PBS twice for 10 min. After blocking
with 5% normal goat serum for 60 min, the sections were
incubated with primary rabbit anti-human MeCP2 (Abcam,
Cambridge, MA) at 4 °C overnight. Binding of the primary
antibody  was  visualized  with  FITC-conjugated  anti-rabbit
secondary antibody (Vector Laboratories, Burlingame, CA)
for 30 min. For double staining, sections were washed and
then incubated with mouse monoclonal anti-α-SMA (Abcam)
for 1 h at room temperature. After washing, sections were
incubated with rhodamine-conjugated anti-mouse secondary
antibody (Vector Laboratories). Sections were mounted in a
mounting medium (Vectashield; Vector Laboratories), and
the  sections  were  examined  with  a  confocal  microscope
(LSM510; Zeiss, Thornwood, NY) using the Zeiss image
acquisition and analysis software (LSM version 3.2). FITC
staining  was  captured  using  a  488-nm  argon  laser  for
excitation  and  a  505-  530-nm  band-pass  emission  filter.
Rhodamine staining was captured using a 543-nm HeNe laser
for excitation and a 560-nm long-pass emission. Negative
controls included omitting the primary antibody and the use
of  IgG  in  place  of  the  primary  antibody  (at  the  same
concentration).
Cell culture: HLE B-3 cells were obtained from ATCC
(Rockville, MD) and cultured in Eagle’s minimum essential
medium (GIBCO BRL, Grand Island, NY) with 20% fetal
bovine  serum,  100  units/ml  penicillin,  and  100  mg/ml
streptomycin at 37 °C in a humidified 5% CO2 atmosphere.
siRNA  transfection:  siRNA  for  MeCP2
(SASI_Hs01_00116141)  and  non-silencing  control
scrambled RNA (Mission-SIC-001-s) were purchased from
Sigma–Aldrich (St. Louis, MO). siRNA was transfected using
the Hiperfect Transfection Reagent (Qiagen, Valencia, CA)
according  to  the  manufacturer’s  instructions.  A  total  of
5×105 cells in 2 ml of medium were seeded in 6-well plates.
siRNA  (final  concentration  10  nM)  was  then  gently
introduced into the cells by mixing with the required amount
of  Hiperfect  Transfection  Reagent.  The  assays  were
performed 72 h post-transfection.
Western  blot  assay:  Confluent  cells  grown  in  6-well
plates in DMEM with 0.4% FBS were lysed, supernatants
were then collected, and proteins were resolved on Tris-HCl
10%  polyacrylamide  gels  at  120  V.  The  proteins  were
transferred  to  a  PVDF  blotting  membrane  (Millipore,
Bedford, MA). The membranes were probed with antibodies
for MeCP2 (Abcam), α-SMA (Abcam), and glyceraldehyde
3-phosphate dehydrogenase (GAPDH; Abcam), respectively,
all  at  1:1,000  dilution.  Membranes  were  washed  and
incubated with a horseradish peroxidase (HRP)-conjugated
secondary antibody (1:3,000; Vector Laboratories) for 30 min
at room temperature. Images were developed using an ECL
chemiluminescence  detection  solution  (Amersham
Pharmacia Biotech, Cleveland, OH).
Statistics: All experiments were performed at least three
times. The data were analyzed using the Student’s t-test, and
a p<0.05 was accepted as significant.
Figure 1. Co-expression of MeCP2 and α-SMA in human PCO membranes. Tissue sections from human PCO membrane were stained by
immunofluorescence for MeCP2 and α-SMA and evaluated by confocal microscopy. MeCP2 and α-SMA were expressed in cells within the
PCO membrane. Merged images show colocalization of MeCP2 and α-SMA. The scale bar is 50 μm.
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MeCP2  and  α-SMA  are  co-expressed  in  human  PCO
membranes: We first evaluated the expression of MeCP2 and
α-SMA in PCO membranes. Three PCO membranes were
evaluated and all showed prominent immunoreactivity for
MeCP2.  Labeling  with  anti-α-SMA  antibodies  revealed
numerous α-SMA-positive transdifferentiated LECs within
the PCO membrane. MeCP2 and α-SMA staining at least
partially  overlapped  in  each  membrane,  indicating  that
MeCP2 and α-SMA were co-expressed in the PCO membrane
(Figure 1). This result raises the possibility that MeCP2 plays
a role in α-SMA expression. Alternatively, MeCP2 and α-
SMA expression could occur in the same cells without any
causal relationship.
MeCP2 is required for TGFβ2-induced α-SMA expression:
We next analyzed whether MeCP2 plays a role in TGFβ2-
induced  α-SMA  expression.  TGFβ2  increased  α-SMA
expression  in  LECs.  However,  when  we  knocked  down
MeCP2  using  MeCP2-specific  siRNA,  TGFβ2  could  not
increase  the  expression  of  α-SMA  (Figure  2).  Therefore,
MeCP2 plays an important role in TGFβ2-induced α-SMA
expression.
Zebularine decreased MeCP2 expression in lens epithelial
cells: In this study, we attempted to find a reagent to inhibit
both TGFβ-induced MeCP2 and α-SMA expression. We have
found that zebularine could inhibit the expression of MeCP2
in retinal pigment epithelial cells (data not published). In this
study,  we  analyzed  zebularine  treatment  on  MeCP2
expression in lens epithelial cells. Our results indicate that
zebularine inhibits MeCP2 expression in a dose-dependent
pattern. As the concentration of zebularine increased from
5 μM to 200 μM, the MeCP2 protein level decreased to 40%
of  untreated  controls  after  zebularine  treatment  for  72  h
(Figure 3A,B). Zebularine also inhibited MeCP2 expression
in a time-dependent pattern. After 1 to 72 h of treatment with
100  μM  zebularine,  the  MeCP2  protein  level  gradually
decreased to 55% of the control level (Figure 3C,D).
Zebularine suppressed TGFβ2-induced α-SMA expression:
Moreover, we investigated whether zebularine also had an
effect on TGFβ2-induced α-SMA expression. After treatment
with TGFβ2, the α-SMA protein level increased 3.5 fold in 72
h. However, the α-SMA remained at a low level if it was
treated with zebularine and TGFβ2 together (Figure 4).
Figure 2. TGFβ2 did not induce α-SMA
expression without MeCP2. A: TGFβ2
increased  α-SMA  expression  in  lens
epithelial cells. However, TGFβ2 could
not increase the expression of α-SMA
after MeCP2 was knocked down using
MeCP2  specific  siRNA.  B:
Densitometry  analysis  of  three
independent  western  blot  analyses
shows  the  quantitative  α-SMA.
*p<0.05. The error bar indicates mean
±SEM.
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In this study, we found that MeCP2 and α-SMA were co-
expressed  in  human  PCO  membranes.  MeCP2  played  an
important role in TGFβ2-induced α-SMA expression in lens
epithelial cells. Zebularine could inhibit MeCP2 expression
and  could  also  suppress  the  TGFβ2-induced  α-SMA
expression.
DNA  methylation  is  a  key  epigenetic  regulatory
mechanism  that  plays  an  important  role  in  α-SMA  gene
expression [10]. Recently, Hu et al. [11] reported that MeCP2
binds to α-SMA and plays a direct activator role for the α-
SMA gene in lung fibroblasts. In the current study, we found
that  TGFβ2  could  not  induce  α-SMA  expression  without
MeCP2, which is consistent with the Hu et al. [11] report.
Therefore,  MeCP2  played  an  important  activator  role  in
TGFβ2-induced LEC epithelial-mesenchymal transition.
The potential mechanisms by which MeCP2 regulates α-
SMA activation are complex. One possibility is that MeCP2
binds  to  the  α-SMA  promoter  and  directly  activates  its
expression. Initially, MeCP2 was known as a transcriptional
repressor that functions by binding to methylated CpG islands
present in the target gene sequence [20]. However, subsequent
studies reveal that only 6% of the MeCP2 binding sites are in
CpG islands. Most of MeCP2-bound promoters belong to
actively  expressed  genes  [21].  Thus,  although  MeCP2
preferentially binds to methylated DNA, it has the potential
to act as both a repressor and an activator of gene expression
[11,12]. Alternatively, MeCP2 may regulate α-SMA through
peroxisome proliferator-activated receptor gamma (PPARγ),
which is a repressor of α-SMA expression. PPARγ is a nuclear
receptor protein that regulates the expression of genes and
plays  essential  roles  in  the  regulation  of  cellular
differentiation.  MeCP2  represses  PPARγ  transcription  by
suppressing  both  transcriptional  initiation  and  elongation
[22]. Therefore, in response to TGFβ, MeCP2 may activate
the expression of α-SMA by inhibiting PPARγ.
The essential role that MeCP2 plays in TGFβ2-induced
α-SMA expression provides a potential target for inhibiting the
epithelial-mesenchymal transition in LECs. Zebularine has
been reported to inhibit MeCP2 expression in some cell lines
[23].  In  preliminary  studies,  we  found  that  zebularine
suppresses  the  expression  of  MeCP2  in  retinal  pigment
epithelial cells (data not published). Therefore, zebularine was
selected for further analysis.
Recent  phase  I  clinical  studies  showed  that  the
methylation  inhibitor  is  well  tolerated  and  safe  [24-26].
Further phase II clinical trials are in progress. The methylation
Figure 3. Zebularine decreased MeCP2
expression  in  LECs.  A:  Zebularine
inhibited MeCP2 expression in a dose-
dependent pattern. As the concentration
of zebularine increased from 5 μM to
200  μM,  the  MeCP2  protein  level
decreased to 40% of the control level
after zebularine treatment for 72 h. C:
Zebularine  also  inhibited  MeCP2
expression in a time-dependent pattern.
After 1 to 72 h of treatment with 100
μM zebularine, the MeCP2 protein level
gradually  decreased  to  55%  of  the
control level. Densitometry analysis of
three independent western blots shows
quantitation of MeCP2 levels (B, D).
*p<0.05. The error bar indicates mean
±SEM.
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2720inhibitor is a new strategy for treating disease. The focus of
our study, zebularine, is a DNA methylation inhibitor. Other
DNA methylation inhibitors, such as 5-Aza-C and 5-Aza-dC,
have  shown  significant  clinical  activity  against  tumors.
However, the clinical use of these agents is complicated by
their toxicity and instability in aqueous solutions [17]. The
half life of zebularine is much longer, and its toxicity is much
lower.  Therefore,  zebularine  offers  a  better  option  for
potential clinical application.
In this study, we found that zebularine suppresses the
expression of MeCP2 in a time- and dose-dependent pattern
in LECs. Furthermore, zebularine suppressed TGFβ2-induced
Figure  4.  Zebularine  suppressed
TGFβ2-induced α-SMA expression. A:
After  TGFβ2  treatment,  the  α-SMA
protein level increased by 3.5 fold in 72
h. However, the α-SMA remained at a
low level if treated with zebularine and
TGFβ2  together.  B:  Densitometry
analysis of three independent western
blots shows the quantitation of α-SMA
levels. *p<0.05. The error bar indicates
mean±SEM.
Figure  5.  Model  for  zebularine
inhibition  of  TGFβ2-induced  LEC-
myofibroblast  transdifferentiation.
MeCP2  plays  an  important  role  in
TGFβ-induced,  LEC-myofibroblast
transdifferentiation, which is an event
marked  by  α-SMA  expression.
Zebularine inhibited not only MeCP2
but  also  TGFβ-induced  α-SMA
expression. Therefore, zebularine could
potentially  prevent  PCO  formation.
LEC=lens  epithelial  cells;  IOL=intra
ocular lens.
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2721α-SMA  expression  (Figure  5).  Therefore,  zebularine  is  a
promising treatment for the possible prevention of PCO after
conventional cataract surgery.
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